Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Potassium canrenoate versus hydrochlorothiazide in hypertension with elevated aldosterone-to-renin ratio and negative confirmatory primary aldosteronism test
2009-017464-17Phase 4Active
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of potassium canrenoate and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Difference in reduction of mean 24-hour systolic blood pressure. Started Apr 2010; status: active.
02
Drugs
potassium canrenoatehydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2009-017464-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017464-17.